Director and Scientific Advisor
Chris currently serves as Chief Scientific Officer of MedGenesis Therapeutix. Until recently he held the position of Chief Scientific Officer of Biovail Corporation until its acquisition by Valeant in June 2010. Previously Chris served as VP & Global Therapeutic Area Head of Neuroscience at Amgen and VP of Neuroscience Discovery Research & Clinical Investigation at Lilly. Until 1998, he was Professor and Head of the Division of Neurological Sciences at the University of British Columbia. Chris received his PhD in Neuropharmacology from Princeton University.
Clinical Pharmacy Pharmaceutical Administration Medicinal Chemistry